Dato-DXd Antibody-Drug Conjugate for Triple-Negative and Hormone Receptor-Positive MBC
Learn about how ADCs work and for research news about Dato-DXd.
ASCO Experts Update Guidance for Sacituzumab Govitecan (Trodelvy®) for HR+, HER2- MBC
Read for information on the FDA’s expanded approval of Trodelvy® and ASCO’s updated guidance on the use of this drug.
Bispecific Antibodies: An Emerging Class Of MBC Drugs
Learn about bispecific antibodies, which bind to two targets instead of one, for MBC treatment.
HER2-Low Expressing: A New Subcategory of HER2-Negative Breast Cancer?
New research shows that stage 4 breast cancer with HER2-low expression can benefit from a new drug. Learn more.
How to Prepare for a Virtual SABCS
SABCS 2020 will be held virtually December 8-11, 2020. Find tips and information to get prepared for this major breast cancer conference.